Evidence map›Paper›PMID 29551650›Full record

ReviewAdvanced drug delivery reviews2018

NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

Yu Jen Jan, Jie-Fu Chen, Yazhen Zhu, Yi-Tsung Lu, Szu Hao Chen, Howard Chung, Matthew Smalley, Yen-Wen Huang, Jiantong Dong, Li-Ching Chen and 6 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 110 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Yu Jen JanUrologic Oncology Program and Uro-Oncology Research Laboratories, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA.
Jie-Fu ChenUrologic Oncology Program and Uro-Oncology Research Laboratories, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yazhen ZhuDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA.
Yi-Tsung LuNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Szu Hao ChenDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA.
Howard ChungDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA.
Matthew SmalleyDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA; CytoLumina Technologies Corp., Los Angeles, CA, USA.
Yen-Wen HuangDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA; CytoLumina Technologies Corp., Los Angeles, CA, USA.
Jiantong DongDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA.
Li-Ching ChenDepartment of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan.
Hsiao-Hua YuInstitute of Chemistry, Academia Sinica, Taipei, Taiwan.
James S TomlinsonDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA, USA; Center for Pancreatic Disease, University of California, Los Angeles, Los Angeles, CA, USA; Department of Surgery, Greater Los Angeles Veteran's Affairs Administration, Los Angeles, CA, USA.
Shuang HouDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA, USA.
Vatche G AgopianDepartment of Surgery, University of California, Los Angeles, Los Angeles, CA, USA; Liver Transplantation and Hepatobiliary Surgery, University of California, Los Angeles, Los Angeles, CA, USA.
Edwin M PosadasUrologic Oncology Program and Uro-Oncology Research Laboratories, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Hsian-Rong TsengDepartment of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: hrtseng@mednet.ucla.edu.
University of California, Los Angeles · USCalifornia NanoSystems Institute · USCedars-Sinai Medical Center · USCytoLumina Technologies (United States) · USCathay General Hospital · TWInstitute of Chemistry, Academia Sinica · TWUniversity of Southern California · US

Funding

Prostate Cancer Bone Metastasis: Biology and TargetingP01CA098912 · NCI · EMORY UNIVERSITY · PI ZAYZAFOON, MAJD · 2003 to 2019
$24.0M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
A blood test to identify prostate cancer patients at risk for visceral metastasisR01CA218356 · NCI · CEDARS-SINAI MEDICAL CENTER · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2017 to 2021
$3.0M
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4M
CTC Purification System Based on Thermoresponsive NanoSubstratesR44CA180482 · NCI · CYTOLUMINA TECHNOLOGIES CORPORATION, INC · PI LIU, SEAN XIAO, TSENG, HSIAN-RONG · 2015 to 2016
$2.0M
Molecular and Functional Analysis of Single Circulating Melanoma CellsR33CA174562 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2013 to 2015
$987k
Advanced Development of An Integrated CTC Enrichment TechnologyR33CA157396 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2011 to 2013
$672k
3D-Nanostrcutured Substrates for Detection of Circulating Tumor CellsR21CA151159 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG · 2010 to 2011
$362k
NCI NIH HHS P01 CA098912NCI NIH HHS P01 CA168585NCI NIH HHS R01 CA218356NCI NIH HHS R21 CA151159NCI NIH HHS R33 CA157396NCI NIH HHS R33 CA174562NCI NIH HHS R44 CA180482NCI NIH HHS U01 CA198900
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are cancer cells shredded from either a primary tumor or a metastatic site and circulate in the blood as the potential cellular origin of metastasis. By detecting and analyzing CTCs, we will be able to noninvasively monitor disease progression in individual cancer patients and obtain insightful information for assessing disease status, thus realizing the concept of "tumor liquid biopsy". However, it is technically challenging to identify CTCs in patient blood samples because of the extremely low abundance of CTCs among a large number of hematologic cells. In order to address this challenge, our research team at UCLA pioneered a unique concept of "NanoVelcro" cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with remarkable efficiency. Four generations of NanoVelcro CTC assays have been developed over the past decade for a variety of clinical utilities. The 1st-gen NanoVelcro Chips, composed of a silicon nanowire substrate (SiNS) and an overlaid microfluidic chaotic mixer, were created for CTC enumeration. The 2nd-gen NanoVelcro Chips (i.e., NanoVelcro-LMD), based on polymer nanosubstrates, were developed for single-CTC isolation in conjunction with the use of the laser microdissection (LMD) technique. By grafting thermoresponsive polymer brushes onto SiNS, the 3rd-gen Thermoresponsive NanoVelcro Chips have demonstrated the capture and release of CTCs at 37 and 4 °C respectively, thereby allowing for rapid CTC purification while maintaining cell viability and molecular integrity. Fabricated with boronic acid-grafted conducting polymer-based nanomaterial on chip surface, the 4th-gen NanoVelcro Chips (Sweet chip) were able to purify CTCs with well-preserved RNA transcripts, which could be used for downstream analysis of several cancer specific RNA biomarkers. In this review article, we will summarize the development of the four generations of NanoVelcro CTC assays, and the clinical applications of each generation of devices.

Indexed as

Cell SeparationMicrofluidic Analytical TechniquesNanotechnologyHumansNanostructuresNeoplastic Cells, CirculatingCell sortingCirculating tumor cellsMicrofluidicsMolecular characterizationNanostructured substratesNanoVelcro Chips

Identifiers

PMID29551650
PMCPMC5993593
OpenAlexW2791040231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.